The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.
Executives urge analysts to focus on the company's long-term potential.
The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union
Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.
Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.
The deal includes a $1.6-billion fee if AbbVie tries to walk away.
An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.
Less-frequent dosing and competitive pricing could spur a shift in market share among products that treat the hereditary blood disorder.
Parent Project Muscular Dystrophy (PPMD) and allied stakeholders recently gave FDA the first patient advocacy-initiated guidance for a rare disease to help accelerate development and review of potential therapies for Duchenne muscular dystrophy.
The rate of decrease in industry's budget for continuing medical education (CME) slowed last year.
Researchers at the Brigham and Women's Hospital found that continuity in color and shape have a significant impact on whether patients stick with a prescription regimen.
Hepatitis C medication Olysio was a star, but the company cautions competition is coming.
The FDA granted Priority Review for consideration of Avastin for some cervical-cancer patients.
Shire and AbbVie's courtship has entered round five. A deal would offer AbbVie tax relief, and possibly make it an acquisition target.
In the latest chapter in the Sovaldi pricing saga, Senators Ron Wyden and Charles Grassley urge Gilead to clarify Sovaldi sticker shock.
Bristol-Myers Squibb is moving forward with its FDA filing of PD-1 Opdivo (formerly known as nivolumab) for patients with advanced melanoma who have been previously treated with the BMS drug Yervoy.
Salix Pharmaceuticals joins the tax-inversion migration by purchasing Cosmo Technologies.
The FDA says the OTC remedy maker's online behavior—including Liking customer Facebook posts—has put the company's drugs in unapproved drug territory.
Two weeks after its $46-billion bid was shot down, AbbVie has revised its offer in hopes of opening up negotiations with Shire.
The drugmaker received a notice from the advertising watchdog over promotion of hep. B treatment Viread in a sponsored link on Google AdWords.
Purdue Pharma expects the FDA to vote yea or nay on the drug by October.
Patients want to do more with mobile and see doctors less. Two studies outline the types of digital interventions patients are interested in.
In what amounts to a sudden about face, CMS wants to delete the Sunshine rule's exclusion for continuing medical education.
The solution: talk to patients.
The consumer-facing edition of The Merck Manual Go-To Home Guide for Symptoms is being released as a mobile app.
The Centers of Disease Control reports that prescribers wrote enough painkiller prescriptions to give one bottle to every adult in the US in 2012.
Allergan's latest pipeline news was a mix of the good and the bad. The good: a potential Lucentis competitor is progressing. The bad: migraine medication Semprana has stalled.
Researchers from Boston Children's Hospital, Harvard Medical School and Brigham and Women's Hospital are offering a bit of internet advice for the Food and Drug Administration: do more.
The FDA approved the inhaled insulin last week.
Following two comprehensive rounds of scoring by more than 100 independent industry judges, the results are in for the MM&M Awards 2014. Here are the five finalists for each of the 31 categories
IMS is offering $520 million cash to add Cegedim's CRM and strategic data business. Cegedim says it will use the money to pay down debt.
An FDA advisory panel voted 11-2 against an accelerated approval for AstraZeneca's experimental PARP inihibitor. The panel recommends getting more data before giving the drug the all-clear.
The firm ended the Phase III trial for its ballyhooed immunotherapy, which showed superior survival compared to chemo in advanced melanoma.
EvaluatePharma's World Preview 2014 has pharma soaring to new lucrative heights in six years' time, buoyed by biologics and a formidable pipeline.
Celebrity endorsement, co-pay cards and online edutainment are some of the ways marketers are dueling for attention in the prescription omega-3 space.
Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.
Four months after announcing a review of low-testosterone treatments for risk of heart attack and stroke, the regulator expanded the classes' warning label to include a general risk of blood clots.
Platform lets pharma firms mine big data, and monitor whether millions spent on ad campaigns or medical education are having the desired effect
An Alzheimer's Association survey finds 59% think the degenerative disease is just part of aging.
Researchers are increasingly using social media to recruit patients, albeit oftentimes in an arms-length manner.
Guidance on promoting products in 140 characters and correcting misinformation serves as a guarded green light, says one observer.
Researchers at Montreal's McGill University survey the explosion in prescription painkiller use and abuse.
The American Diabetes Association has established an across-the-board recommendation that children 18 and younger should keep A1C levels at 7.5% or lower.
An early look at healthcare reforms impact indicates that allowing children to stay on a parent's healthcare plan until they turned 26 did not translate into higher use of medical care, but did lower out-of-pocket healthcare costs for the 19-25 age group.
The health and lifestyle resource's latest app seeks to provide context for all that biometric data consumers are storing in wearables, wireless scales and glucometers.
Patients taking a high-dose form of Novo Nordisk diabetes drug Victoza saw an average weight loss of 5.9% of their body weight, data from a study show.
The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.
The Urban Institute Health Policy Center says putting money behind call centers and person-to-person contact will increase insurance enrollments among Hispanics.
Patients are using their time in the waiting room to better prepare for upcoming discussions with their doctor. That makes it a good time for marketers to offer mobile-friendly info, researchers have found.
Yale researchers find patients are paying more money for newer diabetes medications as they gravitate towards insulin analogs, over human synthetic and animal insulin.
The regulator wants more time to discuss post-marketing requirements.
Researchers argue it makes economic sense to employ Value-Based Insurance Design plans for costly specialty medications.
Researchers find worries about being misunderstood or mixed in with "junk" news are among the reasons academic researchers are keeping their data points out of the social media swirl. Researchers say this fear is at the expense of a faster way to make an impact on public policy.
Merck will test if a pieced-together combo of Idenix's nucleotide inhibitor and its own Breakthrough Therapy regimen can take on the competitive HCV landscape.
The company signed a deal with AstraZeneca in which high-risk heart disease patients can bypass step therapy and go straight to the branded cholesterol fighter.
A coalition of organizations, including pharmaceutical company Sprout, kicked off a campaign urging the FDA to pay as much attention to women's sexual dysfunction needs as it does to men's.
Researchers found that limiting sales rep access and interactions reduces off-label prescriptions for the previously detailed drugs, while also upping off-label prescriptions of the drugs that had not been promoted.
A study shows that veering off the recommended vaccination schedule ups the risk for childhood seizures.
Researchers say switching patients from Lucentis to Avastin eye diseases could save the government $18 billion.
The bedside decision-making app includes clinical trial and drug information as well as breaking news.
The potential of immunotherapy is great, but the news from the 2014 medical meeting shows that great may not be gargantuan in terms of treatment reach.
Will docs line up to glimpse their payment data—and get a chance to correct mistakes—or will low awareness overshadow the latest milestone in the law's roll-out?
Patients will now be able to submit specialty prescriptions at the national chain's retail stores.
The post-Chapter 11 pharmaceutical company unveiled its new name Thursday.
The two drugmakers inked a deal under which Sanofi holds rights to market the ED pill to consumers without a prescription, if the drug can make the switch.
The regulator's latest study will use eye-tracking tools.
Pfizer is taking the heartburn drug from behind the counter to store shelf today. The launch coincides with the scheduled generic entry date.
Pfizer announced Monday that it will no longer pursue AstraZeneca, but industry watchers note it may not really be over.
The pharma market research major is working on unifying into one company with two main product lines, and is also in the process of a re-brand.
The FDA's approval of Takeda's Entyvio puts the drugmaker in the ulcerative colititis and Crohn's mix of prescription treatments.
The FDA's seven-page letter outlines some of the problems the regulator has with one specific Sun site.
The companies announced Tuesday that Arzerra, already indicated for leukemia, failed to outdo Roche's Rituxan in the lymphoma setting.
The advertising watchdog gave drugmaker Alvogen 15 days to make amends.
Both companies revealed Phase-III data for idiopathic pulmonary fibrosis treatments. The progressive disease generally kills patients within three years of diagnosis.
Novartis says the FDA wants more serelaxin efficacy data.
Research evaluating industry's reputation with stakeholders found that biopharma has an opportunity to improve its image with policymakers.
Novartis and Sun agreed generic Gleevec won't surface until February 2016.
The regulator defends its approval decision in a web post.
With pollen season approaching its peak, drugmakers are educating doctors on a new class of allergy tablets. It could be a while before they're made available for patients.
Merck's lead digital health strategist and his business partner offer a glimpse of what's possible through pharma and EHR collaborations.
The two-year collaboration leverages health content from Meredith Vieira's Lives project.
After their merger fell apart, Publicis and Omnicom sought a return to business as usual, including stemming any disruption to personnel or frayed client relationships.
Phase-III results for Eli Lilly basal insulin peglispro showed superior blood sugar reduction vs. Sanofi's Lantus in trials, but a number of safety issues could hurt its appeal.
Analyst reaction to this week's quarterly news reflected a need to woo investors, adding to some negative carryover from the previous year.
The company's 11-country poll found overall awareness about heart failure to be low. The geographic bloc is in the same bucket as the US in terms of mortality rates.
An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.
The firm laid out reasons for why it should remain independent of Pfizer, but analysts say projected earnings are a bit too optimistic and could be a ploy to up the offer.
Pharma has sunk a lot of money into a field that saw $91 billion in sales last year. But those bets come amid turmoil in the US healthcare market, including a tussle over price.
The $14.2-billion deal is expected to close in the second half of this year.
CEO Ian Read told investors Monday that an AZ merger would benefit Astra shareholders and add oomph to its marketing potential. Another exec said he could "envision" filing palbociclib this year, but made no promises.
Merck's ex-blockbuster allergy drug, Singulair, received a thumbs-down from an FDA advisory panel asked to consider an OTC switch.
The response period may have ended in mid-April, but some of the harshest criticisms of FDA's social media draft guidance weren't posted until the end of the month.
The agency's new name, PulseCX, is a nod to its focus on more consumer and strategic-oriented work.
The hiring of Kim Johnson is the latest in a series of changes at inVentiv Health's Palio+Ignite. She talks with MM&M about her goals.
Two drugmakers, Purdue Pharma and Teva, have abuse-deterrent hydrocodone medications either under FDA review or in late-stage testing.
US sales fell 10%, and corruption allegations in China ate into emerging-market sales.
Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.
Sales slipped 1% for the quarter, but the drugmaker couched the financials with news from its much-watched effort in immuno-oncology: that it will wrap its nivolumab filing by the end of this year.